Technological University Dublin

ARROW@TU Dublin
Articles

School of Physics & Clinical & Optometric
Science

2017

Raman Spectroscopy for Cytopathology of Exfoliated Cervical
Cells
Fiona Lyng
Technological University Dublin, Fiona.lyng@tudublin.ie

IR Ramos
Technological University Dublin

Aidan Meade
Technological University Dublin, aidan.meade@tudublin.ie

See next page for additional authors

Follow this and additional works at: https://arrow.tudublin.ie/scschphyart

Recommended Citation
Lyng, F. et al (2016)Raman spectroscopy for cytopathology of exfoliated cervical cells, Faraday Discuss.
2016 Jun 23;187:187-98. doi: 10.1039/c5fd00197h.

This Article is brought to you for free and open access by
the School of Physics & Clinical & Optometric Science at
ARROW@TU Dublin. It has been accepted for inclusion in
Articles by an authorized administrator of ARROW@TU
Dublin. For more information, please contact
arrow.admin@tudublin.ie, aisling.coyne@tudublin.ie.
This work is licensed under a Creative Commons
Attribution-Noncommercial-Share Alike 4.0 License

Authors
Fiona Lyng, IR Ramos, Aidan Meade, O. Ibrahim, M. McMenamin, M. McKenna, and A. Malkin

This article is available at ARROW@TU Dublin: https://arrow.tudublin.ie/scschphyart/93

Raman spectroscopy for cytopathology of exfoliated cervical cells
Ramos IR1,2, Meade AD2, Ibrahim O1,2, Byrne HJ3, McMenamin M4, McKenna M4, Malkin A5, Lyng FM1,2

1

DIT Centre for Radiation and Environmental Science, FOCAS Research Institute, Dublin Institute of

Technology, Kevin St, Dublin 8, Ireland
2

School of Physics, Dublin Institute of Technology, Kevin St, Dublin 8, Ireland

3

FOCAS Research Institute, Dublin Institute of Technology, Kevin St, Dublin 8, Ireland

4

Cytopathology Department, Altnagelvin Hospital, Western Health and Social Care Trust, Derry,

Northern Ireland, United Kingdom
5

School of Biological Sciences, Dublin Institute of Technology, Kevin St, Dublin 8, Ireland

*Corresponding author:
Prof. Fiona M. Lyng
DIT Centre for Radiation and Environmental Science,
FOCAS Research Institute
Dublin Institute of Technology
Kevin St
Dublin 8
Ireland
t: +353 1 4027972
f: +353 1 4027904
e : fiona.lyng@dit.ie

Keywords
Raman spectroscopy, cervical cancer, cervical intraepithelial neoplasia (CIN), low grade squamous
intraepithelial lesion (LSIL), high grade squamous intraepithelial lesion (HSIL),
exfoliated cells

cytopathology,

Abstract
Cervical cancer is the fourth most common cancer affecting women worldwide but mortality can be
decreased by early detection of pre-malignant lesions. The Pap smear test is the most commonly used
method in cervical cancer screening programmes. Although specificity is high for this test, it is widely
acknowledged that sensitivity can be poor mainly due to the subjective nature of this test. There is a
need for new objective tests for the early detection of pre-malignant cervical lesions. Over the past
two decades, Raman spectroscopy has emerged as a promising new technology for cancer screening
and diagnosis. The aim of this study was to evaluate the potential of Raman spectroscopy for cervical
cancer screening using both Cervical Intraepithelial Neoplasia (CIN) or Squamous Intraepithelial Lesion
(SIL) classification terminology. ThinPrep® Pap samples were recruited from a cervical screening
population. Raman spectra were recorded from single cell nuclei and subjected to multivariate
statistical analysis. Normal and abnormal Thinprep samples were discriminated based on the
biochemical fingerprint of the cells using Principal Component Analysis (PCA). Principal Component
Analysis – Linear Discriminant Analysis (PCA-LDA) was employed to build classification models based
on either CIN or SIL terminology. This study has shown that Raman spectroscopy can be successfully
applied to the study of routine cervical cytology samples from a cervical screening programme and
that use of CIN terminology resulted in improved sensitivity for high grade cases.

Introduction
Cervical cancer is the fourth most common cancer in women worldwide, accounting for an estimated
528,000 new cases and 266,000 deaths in 2012.1 However, the mortality associated with cervical cancer
can be significantly reduced if this disease is detected at the early stages of development or at the precancer stage, termed cervical intraepithelial neoplasia (CIN). Cervical cancer mainly affects younger
women, about 60% of cases occurring in women under 50 years of age. Persistent infection with
Human Papillomavirus (HPV) (such as high risk HPV types 16 and 18) is accepted as the major cause for
the development of cervical pre-cancer and cancer.2 Other risk factors include smoking,
immunosuppression, long term use of oral contraceptives and socioeconomic status.3
Cervical cancers are usually preceded by a long phase of pre-invasive disease. This phase is
characterised microscopically as a sequence of events progressing from cellular atypia to various
grades of dysplasia or CIN before progression to invasive carcinoma. Introduced in 1968, CIN is the
most common terminology for cervical histology. It is a three-tiered system, divided into grades 1, 2
and 3, whereby CIN 1 corresponds to mild dysplasia, CIN 2 to moderate dysplasia, and CIN 3
corresponds to both severe dysplasia and carcinoma in situ.4 In cytology, the British Society for Clinical
Cytology (BSCC) reporting system for cervical cancer refers to different grades of dyskaryosis which
relate to the three-tiered CIN terminology with CIN 1 corresponding to mild dyskaryosis, CIN 2
corresponding to moderate dyskaryosis and CIN 3 to severe dyskaryosis. Since then, advances in HPV
research and liquid based cytology led to the introduction of the Bethesda System in the United States
of America.5 According to this nomenclature, squamous intraepithelial lesion (SIL) encompasses a
range of non-invasive cervical epithelial abnormalities, comprising low grade (LSIL) and high grade
lesions (HSIL). Low grade lesions correspond to cellular changes associated with the HPV cytopathic
effect (koilocytotic atypia) and mild dysplasia (CIN 1), whereas high grade lesions correspond to
moderate dysplasia, severe dysplasia, and carcinoma in situ (CIN 2 and 3). The two-tiered terminology
of SIL is the standard reporting system for cervical cytology used in many screening programmes
across developed countries. Since 2012, the College of American Pathologists and the American

Society for Colposcopy and Cervical Pathology has recommended a uniform terminology to describe
the histology of HPV-associated squamous disease across all anogenital sites. The two tiered
terminology of LSIL and HSIL is recommended, as it reflects the biology of transient HPV infections and
persistent precancerous lesions.6 More recently, the BSCC terminology was also revised to comprise
the terms low grade, high grade with the option of high grade dyskaryosis being further reported as
moderate or severe.7 Table 1 summarises the different classification systems.

The gradual progression of cervical cancer can allow the detection of dysplastic changes before
invasive cancer develops through cervical cancer screening programmes. These screening
programmes are common in developed countries, greatly reducing the mortality rates due to cervical
cancer, but are not yet implemented in developing countries due to lack of infrastructure and funding.
The Papanicolaou (Pap) test is the most common screening method for cervical cancer and its
precursor lesions.8 The advantages of the Pap test are that it is non-invasive, inexpensive and widely
accepted. However, although it can have high specificity of up to 95-98%, sensitivity rates can vary
from 74 to 96%, due to sampling, technical and/or interobserver errors which are associated with the
subjective nature of cytological screening.9 There is, therefore, a need for new objective screening
tests for cervical cancer.

Over the past 15 years, excellent sensitivity and specificity values have been reported using vibrational
spectroscopy, InfraRed (IR) and Raman, for the diagnosis of a wide range of cancers, including breast,
prostate, oesophageal, colon, lung, oral and cervical cancer.10-12 IR spectroscopy is based on the
absorption of infrared radiation by the sample and the fact that molecules absorb specific frequencies
of the incident light which are characteristic of their structure. Raman spectroscopy is an optical method
based on inelastic light scattering. The sample is illuminated by monochromatic laser light and
interactions between the incident photons and molecules in the sample result in scattering of the
light. The coupling of the light generates vibrations within the material which are characteristic of the

chemical structure and the energy of the scattered light is reduced by an amount equal to the energy
of the vibrational energy. Thus, the positions, relative intensities and shapes of the bands in a Raman
spectrum carry detailed information about the molecular composition of the sample.
A number of papers by Wong and co-workers in the early 1990’s showed significant differences in
cervical cytology cells between normal, pre-cancer and cancer samples using IR spectroscopy.13-16
However, these initial studies recorded spectra from cell pellets rather than from individual cells and a
number of confounding factors such as neutrophils, endocervical columnar cells, metaplastic cells,
cervical mucus and debris were subsequently identified.17 Similar confounding factors, such as
inflammation, metaplasia, hormonal changes, metabolic activity, blood and mucus, were identified by
other groups.18-22 Nevertheless, an early study by Cohenford and Rigas23 reported an important finding
that morphologically normal exfoliated cells from women with dysplasia or cancer exhibited extensive
IR spectral changes. This finding was confirmed by Schubert et al.24, who showed spectral changes in
cytologically normal cells in dysplastic samples, most likely due to HPV infection. Significant overlap
was observed between negative, LSIL and HSIL cases using ATR—FTIR spectroscopy with maximal
overlap between negative and LSIL cases25. but a more recent study showed that cervical pre-cancer
is more accurately identified when histology rather than cytology is used as the gold standard to
classify the samples.26
There are relatively fewer studies on cervical cytology using Raman spectroscopy, most likely because
of the issues with confounding factors. Vargis et al.27 showed that Raman spectroscopy could classify
HPV-positive and HPV-negative cytology samples with an accuracy of 98.5%. Rubina et al.28 reported a
classification accuracy of ~80% using Raman spectroscopy to distinguish between normal and cervical
cancer cytology samples. Cytology samples were treated with red blood cell lysis buffer prior to Raman
acquisition as the spectra of cervical cancer samples were dominated by blood features. Both of these
studies used cell pellets rather than recording Raman spectra from individual cells and this probably
resulted in the relatively low classification accuracy in the study by Rubina et al. due to sample
heterogeneity. A recent study by Bonnier et al.29 presented new methods for recording Raman spectra

from ThinPrep cervical cytology samples. Pre-treatment of the slides with hydrogen peroxide to clear
blood residue contamination before Raman recording was shown to minimise variability within the
data sets resulting in the collection of highly reproducible data with clear discrimination between
negative cytology and CIN cytology. All data was recorded on glass ThinPrep slides which are currently
used for clinical cervical cytology rather than spectroscopic substrates such as calcium fluoride
substrates which are commonly used in biospectroscopy research studies. Although these substrates
reduce the presence of confounding contributions of the substrate, they are significantly more
expensive which may prohibit clinical applications.30
The aim of this study was to evaluate the potential of Raman spectroscopy for cervical cancer
screening using routine cervical cytology samples from a cervical screening programme. Cytology
samples were classified according to both CIN and SIL terminology and Raman classification models
compared.

Experimental
Sample Collection and slide preparation
166 unstained smear samples in ThinPrepTM slides were obtained from the Western Health & Social
Care Trust Altnagelvin Hospital, Northern Ireland, with the approval of the Research Ethics Committee
Northern Ireland.
Smears were collected, processed via the ThinPrepTM method, Papanicolau (Pap) stained and screened
in the hospital by specialised personnel according to the guidelines in practice. A total of 88 negative,
35 CIN1 (or 35 LSIL) and 21 CIN2 and 22 CIN3 (or 43 HSIL) cases were randomly selected and included
in this study. Each case represents a sample from an individual patient.
One duplicate slide of each selected case was prepared using the ThinPrepTM method, fixed in 100%
ethanol and air-dried. The samples were sent to Dublin Institute of Technology for Raman analysis.
Before recording, each slide was pre-treated with hydrogen peroxidase (H2O2), as per an in-house
protocol29 to remove any contaminating blood and debris.

Raman Microspectroscopy
Raman measurements were performed using a HORIBA Jobin Yvon XploRATM system (Villeneuve
d’Ascq, France), which incorporates an Olympus microscope BX41 equipped with a x100 objective
(MPlanN, Olympus, N.A. 0.9) and a 532nm diode laser source. To avoid any photo damage to the
sample, the power of the laser was set at 50%. The confocal hole was set at 100µm and the 1200
lines/mm grating was used, which gave a spectral dispersion of ~3 cm-1 per pixel. The backscattered
light was collected using an air-cooled CCD detector (Andor, 1024 x 256 pixels) and the spectrometer
was controlled by Labspec V5.0 software. The system was calibrated to the 520.7 cm-1 spectral line of
silicon.
Raman signals from each cell nucleus were integrated twice for 30 seconds in the spectral range of
400-1800cm-1. Spectra from a minimum of 10 cell nuclei were recorded per sample, depending on

the quality of each slide. The data is presented as the average of all 10 cellular spectra recorded
from each individual patient.

Data analysis
Data analysis was performed in Matlab [Mathworks, CA, USA] according to protocols developed in
house.31 Pre-processing of the raw Raman spectra included the application of a Savitsky-Golay filter
(5th order, 13 points) to smooth the spectra and the subtraction of the glass background according to
an in house non-negative least squares (NNLS) model.32 The data set has also been corrected for
baseline and vector normalized to facilitate comparison before principal component analysis (PCA)
was employed to highlight the variability existing in the spectral data set recorded. Principal
component analysis – linear discriminant analysis (PCA-LDA) was also employed to generate a
classification model based on the features highlighted by PCA analysis. The optimal number of
principal components (PCs) to generate the PCA-LDA model was established and 10 fold crossvalidation used to test it. Furthermore, leave one out cross validation (LOOCV) was then used to
evaluate the performance of the PCA-LDA classification model and sensitivity and specificity rates
were calculated for both SIL and CIN classifications.

Results
Mean Raman spectra of cervical cytology samples in the fingerprint region of 400-1800 cm-1 are shown
in figure 1a. The samples are presented according to the SIL classification system; negative, LSIL and
HSIL. The main peaks are indicated and assignments are listed in table 1.33 The mean spectra of
negative, LSIL and HSIL samples show similar features, the main differences being observed around
the 1318/1339 cm-1 region, in which the ratio of the intensities of these two peaks increases from
negative to LSIL and HSIL samples as shown in figure 1b.
To further highlight any differences between the spectral profiles of the samples, PCA was employed.
Figure 2a shows the PCA scatterplot for all SIL classified samples. From the PCA scatterplot, it can be
seen that negative (green), LSIL (magenta) and HSIL (black) samples are separated according to the
first (PC1) and second (PC2) principal components which account respectively for 76.81 % and 7.548
% of the variance explained in the dataset. The loadings for PC1 and PC2 are shown in figure 2b and c.
The negative samples seem to separate from the LSIL samples according to PC1, negative samples
having more DNA (~814 cm-1), protein and lipids (1307, 1446, 1453 cm-1), Amide III (1242 cm-1) and I
(1690 cm-1) also featuring prominently. Furthermore, the negative samples separate to a large extent
from the HSIL samples according to PC2. Negative samples show stronger Amide III (1243, 1375 cm-1)
and protein/lipid (1339 cm-1) features, whereas HSIL samples display stronger Amide I (1606 cm-1) and
Amide II (1544 cm-1). In addition, the PC2 loading also highlights differences in nucleic acids, the
features at 1458 and 1485/7 cm-1 being more prominent in the spectra of negative samples. DNA
features at 481 and 786 cm-1 are more prominent in negative samples, whereas the feature at 893 cm1

is more prominent in HSIL samples. Similarly, phosphate and phosphodiester bonds at 812 cm-1 are

more prominent in HSIL samples, whereas those at 1087-9 cm-1 are more prominent in negative
samples. The separation between LSIL and HSIL samples results from a combination of PC1 and PC2.
Taking the PC1 and PC2 assignments for the negative samples as a reference, the LSIL samples have a
similar PC2 profile to the negative samples whereas the HSIL samples have a similar PC1 profile to the
negative samples.

The PCA results suggest that significant differences can be found in the Raman spectral profile of cell
nuclei to distinguish between negative, LSIL and HSIL samples. PCA-LDA was therefore used to
generate a classification model based on the features highlighted by PCA analysis.Results showed that
a model with 12 PCs was best for LDA. Leave one out cross validation (LOOCV) was then used to
evaluate the performance of the PCA-LDA classification model and sensitivity and specificity rates are
shown in table 3.
Apart from the HSIL sensitivity, the performance of the PCA-LDA model is quite encouraging, all
sensitivity and specificity values being above 90%. Sensitivity is also called the true positive fraction
and accounts for the number of reported positives that are correctly identified as such. As the HSIL
group consists of samples previously classed by the CIN classification system as CIN 2 and CIN 3, it was
decided to re-evaluate the data according to the CIN classification.
Figure 3a shows the mean Raman spectra of CIN 2 and CIN 3 samples. Only small differences can be
observed; a peak at 1246 cm-1 assigned to Amide III and one at 1417 cm-1 assigned to C=C stretching
in a quinoid ring are only observed in CIN 2 spectra whereas the CH3/CH2 twisting or bending mode of
lipid/collagen at 1309 cm-1 is only evident in CIN 3 spectra.
PCA was performed on the dataset according to the CIN classification and the PCA scatterplot is shown
in figure 3b. CIN2 (red) is not clearly separated from the other sample groups but, along PC1, it can be
seen distributed between CIN 3 (black) and CIN 1 (magenta) samples. To further elucidate the
differences between all CIN samples, pairwise PCA was performed on spectra from CIN 1, CIN 2 and
CIN 3 samples and the results are shown in figure 4. CIN 1 and CIN 2 samples show some overlap but
there is some separation along PC1 (figure 4a). PC1 is positively dominated by Amide I (1663 cm-1) and
other protein features (~1309, 1449 cm-1), as shown in figure 4b, indicating that these are more
prominent in CIN2 samples. Similarly, CIN 1 and CIN 3 show some overlap but there is some separation
along PC1 (figure 4c). In this case, PC1 is also positively dominated by Amide I (1669 cm-1) and other
protein features (~1308, 1453 cm-1), as shown in figure 4d, indicating that these are more prominent

in CIN 3 samples compared to CIN 1 samples. CIN 2 and CIN 3 samples show reasonably good
separation with some overlap along PC3 (figure 4e). PC3 is positively dominated by nucleic acid
features at 722, 786, 810 and 850 cm-1 and Amide III at 1242 cm-1, which are more intense in the
spectra of CIN 3 samples, whereas Amide I features at 1651 cm-1 and C-H vibration of proteins and
lipids at 1449 cm-1 are more prominent in the Raman spectra of CIN 2 samples.
For the PCA-LDA of the dataset according to the CIN classification, a model with 14 PCs was best for
LDA and, similar to the SIL classification analysis, LOOCV was then used to evaluate the performance
of the PCA-LDA classification model and sensitivity and specificity rates are shown in table 4. All
sensitivity and specificity values of the PCA-LDA model were greater than 90%.

Discussion
In this study Raman spectra were acquired from the nuclei of single cells of Thinprep cervical cytology
specimens on glass slides. Recording spectra from the cell nuclei may explain the similarity between
the average spectrum of the different sampling groups, as biochemically the nucleus of a normal cell
and the nucleus of an abnormal cell are similar. Several studies have reported increases in nucleic
acids in abnormal tissue samples compared to normal tissue samples.34-37 Abnormal tissue is
characterised by increased cell proliferation rates and therefore more cells are expected to be
detected/scanned (per area) on abnormal samples, resulting in substantial differences compared to
normal tissue samples. In the present study, despite targeting the nuclei of the cells, it is mainly
protein features which seem to discriminate the groups, although some differences in nucleic acid
features were also observed. It should be noted that the Raman signals will have some degree of
contribution from the cytoplasm of the cells as the laser passes through the cell to reach the nucleus.
A previous study of cervical cytology specimens, although conducted on cellular pellets rather than
cell monolayers, reported Amide I (1660 cm-1), ∂CH2 (1450 cm-1) and phenylalanine (1002 cm-1) as the
main features dominating the Raman spectra of negative samples.28 After a treatment to remove
blood from the samples an increase in protein content (at 1006, 1450 and 1660 cm-1) and changes in
their secondary structure due to positive Amide III bands were found. This adds to the case that
instead of concentrating on increases and/or decreases in DNA and nucleic acids, Raman spectroscopy
profiling for cervical cancer diagnosis can benefit from a better understanding of protein assignments.
A change in ratio at 1318/1339 cm-1 was also observed for negative, LSIL and HSIL cases, suggesting a
decrease in the lipid/protein to guanine ratio in LSIL and HSIL samples, which may result from either
a reduction of lipids/proteins and/or an increase in the nucleic acid (guanine) content of these
samples.

The sensitivity and specificity values for the PCA-LDA models generated in this study were extremely
high, especially when compared with Pap screening.9 All values in the CIN classification were greater
than 90% and with the exception of the HSIL sensitivity of ~ 86%, the same was also observed for the
SIL classification. The lower HSIL sensitivity value of 86% seems to suggest that the CIN 2 cases are
from a heterogeneous group and perhaps some of the samples diagnosed as such might be
biochemically closer to CIN 1 than CIN 3 and therefore may not be correctly classified as HSIL.
In fact, a recent study by Doorbar et al.38 which investigated the correlation of CIN classification and
HPV infection status suggested that some reported CIN 2 cases, when analysed by an
immunohistochemistry panel of P16INK4a, MCM and HPV-encoded E4, in fact group with CIN 1 rather
than CIN 3 cases. The study showed that the combination of identification of surrogates of high-risk
HPV E6/E7 activity (P16INK4a and MCM), together with the detection of the abundant HPV-encoded
E4 protein, was able to identify both transient and transforming lesions. This approach not only
allowed to distinguish true papillomavirus infections from similar pathologies but also to divide the
heterogeneous CIN 2 category into those that are CIN 1-like with transient HPV infection expressing
E4, and those that do not express E4 and therefore are more closely related to CIN 3 cases with
transforming HPV infection.

Conclusions
This study has shown that Raman spectroscopy can be successfully applied to the study of Thinprep
cervical cytology samples from a cervical screening programme. Samples were prepared according to
standard protocols and good quality Raman spectra were recorded from unstained single cervical cells
on glass slides. Excellent sensitivity and specificity values were obtained particularly when CIN rather
than SIL terminology was used to classify the samples. This suggests that the HSIL category is quite
heterogeneous with CIN2 cases being biochemically different to CIN3 cases.
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Figure Legends
Figure 1 a) Mean Raman spectra from negative, LSIL and HSIL cervical cytology samples. Shading
denotes the standard deviation, b) 1318/1339 cm-1 peak ratios for negative, LSIL and HSIL cervical
cytology samples.

Figure 2 a) PCA scatterplot, b) PC1 loading and c) PC2 loading of negative, LSIL and HSIL cervical
cytology samples.

Figure 3 a) Mean Raman spectra from CIN 2 and CIN 3 cervical cytology samples. Shading denotes
the standard deviation, b) PCA scatterplot for negative, CIN 1, CIN 2 and CIN 3 cervical cytology
samples.

Figure 4 a) PCA scatterplot and b) PC1 loading for CIN 1 and CIN 2 cervical cytology samples, c) PCA
scatterplot and d) PC1 loading for CIN 1 and CIN 3 cervical cytology samples, e) PCA scatterplot and
f) PC3 loading for CIN 2 and CIN 3 cervical cytology samples.

Table 1 Summary of the different cervical cytology / histology reporting systems
Cervical cytology / histology reporting systems
CIN1

BSCC2 (1996)

1

Mild dyskaryosis

2

Moderate dyskaryosis

SIL3 (Bethesda) /

BSCC (2013)

CAP4 / ASCCP5
LSIL6

Low grade dyskaryosis
High grade dyskaryosis
(moderate)

HSIL7
3

Severe dyskaryosis

High grade dyskaryosis (severe)

1

Cervical intraepithelial neoplasia; 2 British Society for Clinical Cytology; 3 Squamous intraepithelial lesion;

4

College of American Pathologists; 5 American Society for Colposcopy and Cervical Pathology; 6 Low grade

squamous intraepithelial lesion; 7 High grade squamous intraepithelial lesion

Table 2 Tentative peak assignments28 for Raman spectra shown in Figure 1.
Raman shift (cm-1)

Assignment

621

C-C twisting mode of phenylalanine (proteins)

645

C-C twisting mode of phenylalanine (proteins)

722

Adenine

786

DNA: O-P-O; Pyrimidine ring breathing mode

828

Phosphodiester; O-P-O stretching DNA/RNA

856

Amino acid side chain vibrations of proline &
Hydroxyproline, as well as a (C-C) vibration of the
collagen backbone

1032

CH2CH3 bending modes of collagen & phospholipids;
Phenylalanine of collagen; Proline (collagen assignment)

1093

Symmetric PO2- stretching vibration of the DNA
backbone–phosphate backbone vibration as a marker
mode for the DNA concentration C-N of proteins

1127
1175/76

ѵ(C-N)
Cytosine, guanine

1209

Tryptophan & phenylalanine

1240

Amide III; Differences in collagen content; Asymmetric
phosphate stretching modes

1246

Amide III (of collagen)

1307

CH3/CH2 twisting, wagging &/or bending mode
of collagens & lipids

1318

Guanine (ring breathing modes of the DNA/RNA bases)C-H deformation (protein); Amide III (α-helix)

1339

CH2/CH3 wagging & twisting mode in collagen, nucleic
acid & tryptophan

1451

CH2CH3 deformation

1580

C-C stretching

1607

C=C phenylalanine, tyrosine

1617

C=C phenylalanine, tyrosine

1670

Amide I; C=C stretching vibrations; Amide I (anti-parallel
β-sheet); n(C=C) trans, lipids, fatty acids

Table 3 Sensitivity and Specificity from Principal Component Analysis – Linear Discriminant Analysis
(PCA-LDA) Classification of negative, LSIL and HSIL cervical cytology samples
SIL classification
Negative

LSIL

HSIL

Sensitivity

100.00%

94.29%

86.05%

Specificity

97.22%

95.42%

100.00%

Table 4 Sensitivity and Specificity from Principal Component Analysis – Linear Discriminant Analysis
(PCA-LDA) Classification of negative, CIN1, CIN2 and CIN3 cervical cytology samples
CIN classification
Negative

CIN 1

CIN 2

CIN 3

Sensitivity

100.00%

94.29%

100.00%

90.91%

Specificity

97.37%

98.47%

97.24%

100.00%

